Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
ALDERLEY PARK, UK - TheraCryf plc (AIM:TCF), a clinical stage drug development company focusing on neuropsychiatry and oncology, announced today the appointment of Edward Wardle as a Non-Executive Director to its Board. The appointment is effective immediately, with Wardle representing Tracarta Ltd, TheraCryf’s largest shareholder.
Wardle’s experience spans strategy, corporate governance, and business development, and he is currently an investment advisor with Tracarta Ltd and Northern Standard Ltd, as well as a Senior Business Development Executive at Ironveld PLC.
In addition to the board appointment, TheraCryf disclosed the grant of options over a total of 289,820,870 Ordinary Shares under its Long Term Incentive Plan (LTIP), with an exercise price of 0.25 pence per share. These options, which are subject to vesting conditions, are designed to align the interests of senior management with those of shareholders, incentivizing growth in value and achievement of company objectives.
Dr. Alastair Smith, recently appointed as Non-Executive Chair, has agreed to receive his board fees in shares instead of cash for at least the first year of his appointment. Today, he was issued 18,324,000 ordinary shares in lieu of cash remuneration. Smith also participated in the company’s recent funding round, subscribing for 4,000,000 Ordinary Shares in March 2025.
The company is also issuing new Ordinary Shares in lieu of other professional fees. An application will be made for these shares to be admitted to trading on AIM, expected to occur on or around May 2, 2025.
Upon admission, TheraCryf will have a total of 2,148,963,739 Ordinary Shares in issue, with the new figure serving as the denominator for shareholders’ calculations regarding their interest notification obligations under the Financial Conduct Authority’s Disclosure, Guidance and Transparency Rules.
Dr. Smith expressed optimism about Wardle’s contribution to delivering shareholder value and highlighted the focus on neuropsychiatry assets, particularly the Ox-1 antagonist program in addiction.
The announcement is based on a press release statement and provides a transparent view of TheraCryf’s recent corporate actions, including the board appointment, share options grant, and dealings of Persons Discharging Managerial Responsibility (PDMR).
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.